🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Liège
Clinical trial register · Belgium

Clinical Trials in Liège, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Belgium and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3062 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:48 UTC
3062
Studies in scope
all four open statuses
1741
Recruiting now
open to new participants
512
Lead sponsors
across recruiting studies
Top sites
Leuven 1265 Brussels 1116 Ghent 1043 Liège 564 Edegem 437
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca37 AbbVie30 University of Liege29 Janssen Research & Development, LLC26 Centre Hospitalier Universitaire de Liege19
Site location
Leuven1265 Brussels1116 Ghent1043 Liège564 Edegem437
All 201 locations
Target enrolment
to

Trials with a site in Liège

565 of 3062 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Belgium
Start
Recruiting
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
NCT07070232Advanced Solid Tumor
DrugsBNT326·Paroxetine·Itraconazole·Pumitamig
BioNTech SE
Phase 1/2
1,438
Anderlecht, Ghent, Liège, Wilrijk
2025-08-12
Recruiting
An Observational Study to Evaluate Safety, Performance, and Clinical Benefit of BeFlow
NCT07010354Iliac Artery Stenosis, Iliac Artery Occlusion
Bentley InnoMed GmbH
Observational
100
Aalst, Dendermonde, Genk, Liège
2025-08-08
Recruiting
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
NCT07088068Type 1 Diabetes Mellitus
DrugTeplizumab
Sanofi
Phase 3
723
Brussels, Edegem, Jette, Leuven, Liège, Namur
2025-08-06
Recruiting
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
NCT07075016Acute Myeloid Leukemia
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3
227
Antwerp, Brussels, Ghent, Leuven, Liège, Yvoir
2025-08-05
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
NCT07005102Non-Squamous Non-Small Cell Lung Cancer
DrugsTelisotuzumab Adizutecan·Osimertinib·Pemetrexed·Cisplatin
AbbVie
Phase 2/3
854
Hasselt, Leuven, Roeselare, Liège
2025-08-03
Recruiting
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
NCT07044336Endometrial Cancer, Malignant Solid Tumour
DrugsAdriamycin·Taxol·Doxorubicin·Paclitaxel
AstraZeneca
Phase 3
800
Brussels, Charleroi, Edegem, Ghent, Leuven, Liège, Namur
2025-08-01
Recruiting
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
NCT07071519Ulcerative Colitis
DrugRisankizumab
AbbVie
Phase 3
120
Brussels, Liège
2025-07-28
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
NCT06953960Multiple Myeloma
DrugsEtentamig·Pomalidomide·Daratumumab·Dexamethasone
AbbVie
Phase 1/2
325
Ghent, Leuven, Liège
2025-07-23
Recruiting
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
NCT06758401Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsSigvotatug vedotin·Pembrolizumab
Pfizer
Phase 3
714
Mechelen, Brussels, Charleroi, Brasschaat, Liège
2025-07-23
Recruiting
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
NCT06570798Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis
DrugsUplizna·Inebilizumab·Blinatumomab
Amgen
Phase 2
220
Brussels, Ghent, Leuven, Liège
2025-07-16
Recruiting
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
NCT07284121Lung Cancer, Hepatocellular Carcinoma
DrugAtezolizumab
Hoffmann-La Roche
Observational
700
Auderghem, Ghent, Haine-Saint-Paul, Liège, Merksem, Mont-godinne
2025-07-15
Recruiting
A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44
NCT07037862Duchenne Muscular Dystrophy (DMD)
DrugENTR-601-44
Entrada Therapeutics, Inc.
Phase 1/2
24
Ghent, Leuven, Liège
2025-06-30
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
DrugsEpirubicin·Sacituzumab tirumotecan·Olaparib·Doxorubicin
Merck Sharp & Dohme LLC
Phase 3
2,400
Liège, Hasselt, Aalst, Ghent, Namur
2025-06-30
Recruiting
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
NCT06937086Ulcerative Colitis, Obesity or Overweight
DrugsMirikizumab·Tirzepatide
Eli Lilly and Company
Phase 3
350
Aalst, Brussels, Kortrijk, Leuven, Liège
2025-06-26
Recruiting
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
NCT06937099Crohn's Disease, Obesity or Overweight
DrugsMirikizumab·Tirzepatide
Eli Lilly and Company
Phase 3
290
Aalst, Brussels, Kortrijk, Leuven, Liège
2025-06-26
Active, closed
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
NCT06832618Atopic Dermatitis
DrugRuxolitinib
Incyte Corporation
Phase 3
159
Brussels, Ghent, Gilly, Liège, Maldegem
2025-06-17
Active, closed
NeVa Retrospective Comparative SR Study
NCT06964724Stroke Acute
Vesalio
Observational
800
Liège
2025-06-15
Recruiting
ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT06902558Autosomal Dominant Polycystic Kidney Disease
Calico Life Sciences LLC
Phase 2
240
Brussels, Liège, Leuven
2025-06-09
Active, closed
A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy
NCT06821542Chronic Graft-versus-host-disease
DrugAxatilimab
Incyte Corporation
Phase 3
9
Bruges, Godinne-mont, Leuven, Liège, Roeselare, Woluwe-Saint-Lambert
2025-06-04
Recruiting
Transcutaneous Auricular Vagus Nerve Stimulation for Persistent Post-concussion Symptoms
NCT07017257Persistent Post-concussive Symptoms
University of Liege
Not applicable
48
Liège
2025-05-28
Recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
NCT06952504Endometrial Cancer
DrugsSacituzumab tirumotecan·Docetaxel·Paclitaxel·Cisplatin
Merck Sharp & Dohme LLC
Phase 3
1,123
Brussels, Ghent, Leuven, Charleroi, Liège
2025-05-22
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·5-FU·Adrucil·Capecitabine
Astellas Pharma Global Development, Inc.
Phase 3
500
Bonheiden, Brussels, Edegem, Ghent, Leuven, Liège
2025-05-22
Recruiting
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370Heart Failure
DrugsVicadrostat·Dapagliflozin
Boehringer Ingelheim
Phase 3
4,200
Genk, Ghent, Gilly, La Louvière, Liège
2025-05-20
Recruiting
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
NCT06977581Asthma
DrugTilrekimig
Pfizer
Phase 2
252
Mechelen, Ghent, Liège
2025-05-20
Recruiting
Spontaneous Eye Blinking in Disorders of Consciousness
NCT06323031Disorders of Consciousness
Fondazione Don Carlo Gnocchi ETS
Observational
70
Liège
2025-05-08
Recruiting
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
NCT06652438Acute Myeloid Leukemia, Adult
DrugRevumenib
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3
448
Antwerp, Bruges, Brussels, Ghent, Hasselt, Leuven, Liège, Yvoir
2025-05-05
Active, closed
A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)
NCT06924970Sickle Cell Disease
DrugTebapivat
Agios Pharmaceuticals, Inc.
Phase 2
59
Liège
2025-05-01
Recruiting
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310Carcinoma, Non-Small-Cell Lung
DrugsAdagrasib·Pemetrexed·Cisplatin·Carboplatin
Mirati Therapeutics Inc.
Phase 3
630
Brussels, Hasselt, Ghent, Leuven, Liège
2025-04-24
Active, closed
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
NCT06934226Plaque Psoriasis
DrugsIcotrokinra·Ustekinumab
Janssen Research & Development, LLC
Phase 3
752
Brussels, Ghent, Leuven, Liège, Maldegem
2025-04-15
Recruiting
Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation-2 (TELSTAR-2)
NCT06549426Coma, Electrographic Status Epilepticus
University of Twente
Not applicable
150
Brussels, Charleroi, Liège, Louvière, Ottignies
2025-04-10
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
NCT06868277Carcinoma, Non-Small Cell Lung
DrugsRilvegostomig·Keytruda·Pembrolizumab
AstraZeneca
Phase 3
830
Edegem, Jette, Libramont-Chevigny, Liège, Mechelen, Roeselaere
2025-04-10
Recruiting
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
NCT06824467Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
DrugsSteroid mouthwash (dexamethasone·Mvasi·Acetaminophen·Avastin
Merck Sharp & Dohme LLC
Phase 3
770
Edegem, Liège, Ghent, Leuven, Namur
2025-04-09
Recruiting
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
NCT06801834Extensive Stage Small Cell Lung Cancer (ES-SCLC)
DrugsAmrubicin·Lurbinectedin·Topotecan·Sacituzumab Govitecan
Gilead Sciences
Phase 3
695
Charleroi, Hasselt, Liège, Roeselare, Sint-Niklaas
2025-04-04
Recruiting
The Dragon PLC Trial (DRAGON-PLC)
NCT06914648Primary Liver Cancer, Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
Maastricht University
Not applicable
358
Brussels, Antwerp, Ghent, Liège, Yvoir, Hasselt, Jette, Kortrijk
2025-04-01
Recruiting
Episodes of (Dis)Connected Consciousness in ICU Survivors
NCT07048951Consciousness, Near Death Experience, ICU, Critical Illness
University of Liege
Observational
200
Liège
2025-04-01
Not yet open
Effects of Virtual Reality Hypnosis on Anxiety, Pain and Comfort in Oncology Patients During a Port-catheter Placement Procedure
NCT06883786Cancer
University of Liege
Not applicable
102
Huy, Liège
2025-04
Recruiting
Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
NCT06830759Diffuse Large B-cell Lymphoma, Follicular Lymphoma
AbbVie
Observational
700
Brasschaat, Jette, Boussu, Charleroi, La Louvière, Liège, Genk, Sint-Niklaas
2025-03-28
Recruiting
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
NCT06989112Endometrial Cancer
DrugsTaxotere·Rilvegostomig·Paraplatin·Taxol
AstraZeneca
Phase 3
600
Anderlecht, Brussels, Charleroi, Ghent, Leuven, Liège
2025-03-27
Recruiting
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
NCT06644781Esophageal Squamous Cell Carcinoma
DrugsIfinatamab Deruxtecan·Irinotecan·Docetaxel·Paclitaxel
Daiichi Sankyo
Phase 3
510
Brussels, Edegem, Leuven, Liège
2025-03-27
Recruiting
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
NCT06914128MTAP-deleted Solid Tumors
Bayer
Phase 1/2
450
Antwerp, Ghent, Leuven, Liège
2025-03-21
Active, closed
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
NCT06840392Hidradenitis Suppurativa
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
565
Brussels, Leuven, Liège
2025-03-20
Recruiting
Frequency of Occurrence and Risk Factors of Postoperative Nausea and Vomiting During Elective C-section Under Spinal Anesthesia With Preventive Medication
NCT06927830Nausea and Vomiting, Postoperative, Cesarean Delivery, Spinal Anesthesia, Antiemetic Therapy
University of Liege
Observational
400
Chenée, Liège
2025-03-19
Recruiting
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
NCT06819007Ovarian Cancer
DrugsTrastuzumab deruxtecan·Bevacizumab
Daiichi Sankyo
Phase 3
582
Ghent, Leuven, Liège, Namur, Woluwe-Saint-Lambert
2025-03-19
Recruiting
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878Moderately to Severely Active Crohns Disease
DrugAfimkibart
Hoffmann-La Roche
Phase 3
600
Aalst, Brussels, Edegem, Ghent, Hasselt, Liège, Mons, Sint-Niklaas
2025-03-17
Recruiting
Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake
NCT06571149Ischemic Stroke
DrugsAlteplase·Tenecteplase
Insel Gruppe AG, University Hospital Bern
Phase 4
906
Bruges, Brussels, Charleroi, Ghent, Kortrijk, Leuven, Liège
2025-03-14
Recruiting
A Study to Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced Coagulopathy
NCT06854640Sepsis, Coagulopathy
DrugBAY3389934
Bayer
Phase 1
36
Edegem, Woluwe-Saint-Lambert, Ottignies, Liège
2025-03-12
Active, closed
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
NCT06858839Obesity
DrugMaridebart cafraglutide
Amgen
Phase 3
3,853
Edegem, Ghent, Kortrijk, Leuven, Liège, Mechelen, Mons
2025-03-12
Recruiting
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
NCT06772623Non Small Cell Lung Carcinoma
DrugsBudigalimab·Telisotuzumab Adizutecan·Pemetrexed·Cisplatin
AbbVie
Phase 1/2
252
Liège, Hasselt, Sint-Niklaas, Roeselare
2025-03-06
Active, closed
An Ophthalmic Safety Study in Patients With Breast Cancer
NCT06767462Ophthalmic Safety in Patients With Breast Cancer
AstraZeneca
Observational
160
Leuven, Liège
2025-03-05
Recruiting
A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)
NCT06796907Tumours, Gynecological
DrugsMo-Rez·Dostarlimab·Bevacizumab
GlaxoSmithKline
Phase 1/2
305
Brussels, Ghent, Leuven, Liège
2025-03-04
Recruiting
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
NCT06671483Psoriatic Arthritis
DrugZasocitinib
Takeda
Phase 3
1,088
Anderlecht, Ghent, Genk, Brussels, Liège
2025-03-03
Recruiting
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
NCT06764875HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
DrugsRilvegostomig·Trastuzumab deruxtecan·Adrucil·Trastuzumab
AstraZeneca
Phase 3
840
Edegem, Ghent, Leuven, Liège
2025-03-01
Recruiting
Impact of Anesthesia, Positive Pressure Ventilation and Modality of Imaging on the Echocardiographic Assessment of the Severity of Aortic Regurgitation
NCT06835946Aortic Regurgitation Disease, Aortic Insufficiency
University of Liege
Observational
100
Liège
2025-03-01
Recruiting
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
NCT06855498Hidradenitis Suppurativa (HS)
DrugPovorcitinib
Incyte Corporation
Phase 3
600
Brussels, Ghent, Liège, Loverval, Woluwe-Saint-Lambert
2025-02-28
Recruiting
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
NCT06731478Gastric Cancer, Gastroesophageal Junction Cancer
DrugsTrastuzumab deruxtecan·Trastuzumab·Keytruda·Pembrolizumab
Daiichi Sankyo
Phase 3
726
Anderlecht, Bruges, Brussels, Leuven, Liège, Namur
2025-02-27
Recruiting
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
NCT06646276Extensive-Stage Small Cell Lung Cancer
DrugsEtoposide·Atezolizumab·Nivolumab·Carboplatin
Bristol-Myers Squibb
Phase 3
530
Brussels, Ghent, Sint-Niklaas, Liège
2025-02-25
Active, closed
A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection in Belgium
NCT06677892Cytomegalovirus (CMV)
Takeda
Observational
66
Anderlecht, Brussels, Edegem, Ghent, Jette, Leuven, Liège, Yvoir
2025-02-24
Recruiting
Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma
NCT06558604Lymphoma, Mantle-Cell
DrugsVenclyxto·Glofitamab·Zanubrutinib·Obinutuzumab
The Lymphoma Academic Research Organisation
Phase 2
100
Bruges, Brussels, Liège, Yvoir
2025-02-21
Recruiting
A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer
NCT06567782Neoplasms, Colon
DrugsCapeox·Dostarlimab
GlaxoSmithKline
Phase 2
120
Aalst, Bonheiden, Brussels, Ghent, Leuven, Liège, Ostend, Roeselare
2025-02-18
Active, closed
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
NCT06619236Platinum-resistant Ovarian Cancer
DrugsRina-S·Pegylated liposomal doxorubicin·Topotecan·Gemcitabine
Genmab
Phase 3
530
Turnhout, Aalst, Brussels, Charleroi, Leuven, Liège, Roeselare
2025-02-07
Recruiting
LEOPARD Training and Validation Data Collection Study
NCT06675604Decompensated Liver Cirrhosis, Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, Hepato-cellular Carcinoma
Assistance Publique - Hôpitaux de Paris
Observational
4,500
Brussels, Ghent, Leuven, Liège
2025-02-04
Recruiting
Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD)
NCT06897839Bronchopulmonary Dysplasia
Airway Therapeutics, Inc.
Phase 2/3
366
Antwerp, Brussels, Leuven, Liège
2025-02-03
Recruiting
A Prospective Randomised Study of Treatment Selection Based on Epigenetic Markers Versus Standard of Care Treatment Selection in Adults With CROHN's Disease
NCT07363044Crohn Disease (CD)
Alimentiv Inc.
Not applicable
378
Antwerp, Bonheiden, Brasschaat, Brussels, Edegem, Ghent, Leuven, Liège
2025-02-01
Recruiting
An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis
NCT06764693Psoriatic Arthritis
AbbVie
Observational
1,200
Anderlecht, Charleroi, Genk, Aalst, Leuven, Liège
2025-01-31
Recruiting
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
NCT06100289Ulcerative Colitis, Crohn's Disease
DrugVedolizumab
Takeda
Phase 3
70
Brussels, Liège
2025-01-22
Recruiting
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
NCT06740630Chickenpox
DrugsHepatitis A vaccine·MMR vaccine·PCV (pneumococcal conjugate vaccine) 13·PCV 20
GlaxoSmithKline
Phase 3
1,840
Brussels, Ghent, Gozée, Leuven, Liège
2025-01-10
By invitation
Effect of Nicotine Gingival Fibroblast Intoxication on the Response of Periodontal Treatment
NCT07491627Periodontitis, Smoking Cessation, Tobacco Dependence
University of Liege
Not applicable
56
Liège
2025-01-06
Recruiting
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
NCT06227910Crohn's Disease
DrugsVedolizumab·Upadacitinib
Takeda
Phase 3
396
Brussels, Bonheiden, Ghent, Leuven, Liège
2025-01-02
Active, closed
A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy
NCT06742190Multifocal Motor Neuropathy (MMN), MMN
DrugsEmpasiprubart·Immunoglobulin·IVIG
argenx
Phase 3
154
Edegem, Leuven, Liège
2024-12-18
Recruiting
Phase III Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents
NCT06745557Burns
DrugsDenovoSkin·Ehsg-Kf
CUTISS AG
Phase 3
70
Liège
2024-12-13
Active, closed
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
NCT06628310Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
DrugsBudigalimab·Telisotuzumab Adizutecan·Leucovorin·Fluorouracil
AbbVie
Phase 2
185
Brasschaat, Leuven, Liège
2024-12-13
Recruiting
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
NCT06750094Colorectal Neoplasms
DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Adrucil·Cetuximab
Janssen Research & Development, LLC
Phase 3
700
Anderlecht, Edegem, Ghent, Haine Saint Paul La Louviere, Kortrijk, Leuven, Liège
2024-12-12
Recruiting
A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis
NCT06636656Ulcerative Colitis
Boehringer Ingelheim
Phase 2
80
Leuven, Liège
2024-12-11
Active, closed
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
NCT06691984Metastatic Castration-resistant Prostate Cancer
DrugsXaluritamig·Cabazitaxel·Abiraterone·Enzalutamide
Amgen
Phase 3
707
Brussels, Ghent, Kortrijk, Liège
2024-12-09
Active, closed
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
NCT06588686Idiopathic Pulmonary Fibrosis (IPF)
Vicore Pharma AB
Phase 2
378
Brussels, Liège, Yvoir
2024-12-09
By invitation
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT06679946Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
DrugVutrisiran
Alnylam Pharmaceuticals
Phase 3
700
Aalst, Anderlecht, Dendermonde, Ghent, Hasselt, Leuven, Liège, Roeselare
2024-12-03
Recruiting
Study on the Clinical Efficacy of Teclistamab and Talquetamab
NCT06477783Multiple Myeloma, Hematologic Diseases
DrugTeclistamab
Universitaire Ziekenhuizen KU Leuven
Observational
100
Bonheiden, Edegem, Charleroi, Hornu, Mons, Hasselt, Liège, Yvoir
2024-12-01
Active, closed
Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine
NCT06543914Migraine
AbbVie
Observational
1,314
Brussels, Jette, La Louvière, Liège, Aalst, Bruges, Kortrijk
2024-11-26
Active, closed
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
NCT06635824PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
DrugsDocetaxel·Pembrolizumab
Genmab
Phase 3
191
Brussels, Gilly, Hasselt, Liège, Mechelen, Roeselare
2024-11-25
Recruiting
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
NCT06617325Systemic Lupus Erythematosus
UCB Biopharma SRL
Phase 3
450
Leuven, Liège
2024-11-21
Recruiting
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
NCT06690775Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Endometrioid Ovarian Cancer
DrugsTORL-1-23·Pegfilgrastim
TORL Biotherapeutics, LLC
Phase 2
230
Edegem, Woluwe-Saint-Lambert, Leuven, Liège
2024-11-20
Active, closed
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247Leukemia
DrugQuizartinib
Daiichi Sankyo
Phase 3
700
Anderlecht, Antwerp, Bruges, Brussels, Leuven, Liège, Roeselare
2024-11-19
Recruiting
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457Metabolic Dysfunction Associated Steatohepatitis
Boehringer Ingelheim
Phase 3
1,590
Brussels, Edegem, Genk, Liège
2024-11-12
Active, closed
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
NCT06676319Asthma
DrugsBudesonide/Formoterol·Lunsekimig
Sanofi
Phase 2
556
Liège, Mechelen
2024-11-07
Recruiting
EXtensive mulTilayer stEnt treatmeNt in Aortic disSectiOn
NCT06675617Type B Aortic Dissection
Intressa Vascular SA
Not applicable
72
Genk, Leuven, Liège
2024-10-30
By invitation
Combined Effect of TCC-I and BATD on Depressive Symptoms and Insomnia
NCT06633263Depression - Major Depressive Disorder, Insomnia
University of Liege
Not applicable
12
Liège
2024-10-21
Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786Colorectal Neoplasms
DrugsLeucovorin calcium/Levoleucovorin·Erbitux·Amivantamab·Adrucil
Janssen Research & Development, LLC
Phase 3
1,000
Anderlecht, Edegem, Ghent, Haine Saint Paul La Louviere, Kortrijk, Leuven, Liège
2024-10-18
Active, closed
A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
NCT06643481Amyotrophic Lateral Sclerosis (ALS)
DrugVHB937
Novartis Pharmaceuticals
Phase 2
251
Leuven, Liège
2024-10-17
Recruiting
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
Boehringer Ingelheim
Phase 3
1,800
Brussels, Edegem, Genk, Ghent, Leuven, Liège, Namur, Roeselare
2024-10-14
Active, closed
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
NCT06388564Chronic Graft-versus-host-disease
DrugsAxatilimab·Prednisolone·Ruxolitinib·Methylprednisolone
Incyte Corporation
Phase 2
130
Bruges, Edegem, Hasselt, Leuven, Liège, Roeselare
2024-10-11
Active, closed
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
NCT06516965Prurigo Nodularis
DrugPovorcitinib
Incyte Corporation
Phase 3
346
Bruges, Ghent, Gilly, Liège, Woluwe-Saint-Lambert
2024-10-10
Recruiting
Fertility and Ovarian Reserve in Female Childhood Cancer Survivors
NCT06626282Childhood Cancer Survivors, Fertility, Ovarian Reserve, CED
Centre Hospitalier Universitaire de Liege
Observational
340
Liège, Brussels
2024-10-09
Recruiting
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
NCT06598306Extensive Stage Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 1
220
Ghent, Leuven, Liège
2024-10-07
Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT06561386Non-small Cell Lung Cancer
DrugsRelatlimab·Pemetrexed·Nivolumab·Cisplatin
Bristol-Myers Squibb
Phase 3
1,000
Edegem, Brussels, Hasselt, Yvoir, Roeselare, Liège
2024-10-07
Recruiting
Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
NCT05947955Acute Respiratory Distress Syndrome, Infections
BioAegis Therapeutics Inc.
Phase 2
600
Brussels, Charleroi, Liège, Ottignies
2024-10-03
Active, closed
Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.
NCT06473779Severe Asthma
AstraZeneca
Phase 3
326
Anderlecht, Edegem, Erpent, Ghent, Liège
2024-09-30
Recruiting
Study to Assess Treatment Patterns and Outcomes With Upadacitinib in Adult Participants With Inflammatory Bowel Disease in Belgium
NCT06581042Ulcerative Colitis, Crohn's Disease
AbbVie
Observational
280
Bonheiden, Anderlecht, Lodelinsart, Tournai, Liège, Genk, Ghent, Sint-Niklaas
2024-09-27
Active, closed
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
NCT06525220Head and Neck Squamous Cell Carcinoma
DrugsPetosemtamab·Pembrolizumab
Merus B.V.
Phase 3
699
Brussels, Edegem, Ghent, Leuven, Liège, Namur
2024-09-25
Active, closed
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06497556Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
DrugsDivarasib·Sotorasib·Adagrasib
Hoffmann-La Roche
Phase 3
338
Aalst, Brussels, Edegem, Hasselt, Liège, Mont-godinne, Roeselare, Sint-Niklaas
2024-09-23
Active, closed
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
NCT06558279Myasthenia Gravis, Ocular
argenx
Phase 3
141
Leuven, Liège
2024-09-18
Rows per page Showing 101–200 of 565
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Belgian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 28 September 2026. https://priyalifescience.com/clinical-trials-belgium/city/li-ge?page=2

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Belgium and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,062 studies in total at the last sync on 26 Sep 2026, 19:48 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 565 of those studies with a site in Liège.

How many clinical trials are recruiting in Liège?

289 of the 565 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:48 UTC sync. A further 16 have not yet opened recruitment, 247 are active but closed to new participants, and 13 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.